Document is current

Article History

Received: 25 September 2025

Accepted: 4 April 2026

First Online: 16 April 2026

Competing interests

: The authors declare the following competing interests: AH, JB, CGS, SAP, AI, KO, AWL, JH, EW, TD, and LJ report no disclosures relevant to the manuscript. FB has served as national coordinator and principal investigator for clinical trials sponsored by Biogen, Roche, Axovant and Eisai. BFB has served as an investigator for clinical trials sponsored by Biogen and Alector. He receives royalties from the publication of a book entitled Behavioural Neurology of Dementia (Cambridge Medicine, 2017), serves on the Scientific Advisory Board of the Tau Consortium, and receives research support from NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, and the Ted Turner and Family Foundation LBD Functional Genomics Program. DA has received research support and/or honoraria from AstraZeneca, H. Lundbeck, Novartis Pharmaceuticals and GE Health, and served as paid consultant for H. Lundbeck, Eisai and Evonik. KK serves on the data safety monitoring board for Takeda Global Research and Development Center, Inc., receives research support from Avid Radiopharmaceuticals and Eli Lilly, and receives funding from NIH and Alzheimer’s Drug Discovery Foundation. DF consults for BioArctic and has received honoraria from Esteve.